Generate Investment Management Ltd bought a new stake in shares of Danaher Co. (NYSE:DHR – Free Report) during the 4th quarter, Holdings Channel.com reports. The firm bought 35,043 shares of the conglomerate’s stock, valued at approximately $8,044,000.
A number of other institutional investors have also recently added to or reduced their stakes in DHR. Golden State Wealth Management LLC acquired a new position in shares of Danaher during the fourth quarter worth about $31,000. Lecap Asset Management Ltd. acquired a new position in Danaher during the 4th quarter worth approximately $2,891,000. Live Oak Private Wealth LLC boosted its holdings in Danaher by 5.2% in the 4th quarter. Live Oak Private Wealth LLC now owns 43,789 shares of the conglomerate’s stock worth $10,052,000 after acquiring an additional 2,151 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in Danaher by 3.7% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 81,180 shares of the conglomerate’s stock valued at $18,635,000 after acquiring an additional 2,890 shares in the last quarter. Finally, Strategic Financial Concepts LLC purchased a new stake in shares of Danaher during the fourth quarter valued at approximately $31,000. 79.05% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.90% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Danaher Trading Down 1.5 %
Shares of NYSE DHR opened at $206.92 on Friday. Danaher Co. has a 12-month low of $205.79 and a 12-month high of $281.70. The company has a market cap of $149.45 billion, a price-to-earnings ratio of 39.19, a price-to-earnings-growth ratio of 2.80 and a beta of 0.83. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock’s 50 day simple moving average is $233.38 and its 200 day simple moving average is $252.10.
Danaher (NYSE:DHR – Get Free Report) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the previous year, the business earned $2.09 EPS. Equities research analysts expect that Danaher Co. will post 7.77 EPS for the current year.
Danaher Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s payout ratio is currently 20.45%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- How Technical Indicators Can Help You Find Oversold Stocks
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- 3 Tickers Leading a Meme Stock Revival
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- Where to Find Earnings Call Transcripts
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.